Transplant-Eligible, CAR T Considered: How Do We Decide?

Opinion
Video

Panelists discuss how, when selecting among chimeric antigen receptor T-cell (CAR T) therapies, medical professionals typically consider several key factors: the specific cancer type and its CD19/BCMA expression, FDA-approved indications for each therapy, the patient’s prior treatments and response history, the therapy’s documented efficacy and safety profile, manufacturing time and availability, and center-specific experience with different products. Patient-specific factors like comorbidities and disease burden also influence the decision.

Recent Videos
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
4 experts in this video
4 experts in this video
2 experts in this video
Related Content